Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The combination of an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin-receptor blocker (ARB) increases the risk for serious adverse effects in patients with diabetic nephropathy, according to NEPHRON-D, a large multicenter study that was stopped early.
The research, known as the Veterans Affairs Nephropathy in Diabetes study, was presented here at Kidney Week 2013 and was also published in the New England Journal of Medicine (2013;369:1892-1903).
Investigators report that hyperkalemia was significantly higher with combination therapy than with monotherapy (6.3 vs 2.6 events per 100 person-years; P < .001), as was acute kidney injury (12.2 vs 6.7 events per 100 person-years; P < .001).
http://www.medscape.com/viewarticle/814654
The research, known as the Veterans Affairs Nephropathy in Diabetes study, was presented here at Kidney Week 2013 and was also published in the New England Journal of Medicine (2013;369:1892-1903).
Investigators report that hyperkalemia was significantly higher with combination therapy than with monotherapy (6.3 vs 2.6 events per 100 person-years; P < .001), as was acute kidney injury (12.2 vs 6.7 events per 100 person-years; P < .001).
http://www.medscape.com/viewarticle/814654